Covid Treatment Pill Is Out – Here Are The Latest Reports

Covid Treatment Pill Is Out – Here Are The Latest Reports
SHARE

Viable treatments for the novel coronavirus have been making headlines, and now, according to the latest reports, more reasons to celebrate are here.

According to a new article posted by The Guardian, covid-19 has quietly but surely become the gift that keeps on giving for big pharma.

“The past two years have seen it reap huge profits from Covid vaccines, while simultaneously opposing wider sharing of the technology required to make them. And now there’s a new money-spinner on the rise: Covid antiviral treatment pills. Once again, we’re poised to fall into the same inequality traps we’re caught in with the global vaccine rollout.”

The same article mentioned above notes the fact that both Pfizer and Merck have new antiviral pills rapidly arriving on the market – Paxlovid and molnupiravir respectively.

Massive incomes from vaccines 

The same publication notes the fact that the same way in which things happened with the vaccines that came before them, both corporations have made it their business to ultimately decide who gets to make generic versions through the medical patent system.

Source: Pixabay
Source: Pixabay

This was and still is a crucial, life-saving question for millions around the world.

“And business certainly looks promising. Pfizer alone, freshly cemented as the global Covid-19 vaccine kingpin, expects to make as much as $22bn from its new pill this year, on top of $37bn it made in 2021 from the vaccine.”

Anyway, we suggest that you check out the complete article in order to learn more available news. 

Pfizer board member says the end of the pandemic is around the corner 

It’s been just revealed that an extremely important pharmaceutical executive is saying that pandemic-related restrictions could be relaxed.

This is happening as cases decline in some areas following a surge of the milder Omicron variant.

Dr. Scott Gottlieb is a former director of the Food and Drug Administration (FDA) and current board member at Pfizer. 

“I think certainly on the East Coast, where you see cases declining dramatically, we need to be willing to lean in and do that very soon I think as conditions improve we have to be willing to relax some of these measures with the same speed that we put them in place.”

Stay tuned for more news. 


SHARE
Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.